Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gecacitinib in Ruxolitinib-Refractory/Intolerant Acute GVHD
NCT07197112Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of jaktinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Ruijin Hospital. Primary endpoint: Overall Response Rate at 28 days. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07197112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197112.